Scilex Holding Co (SCLXW) stock
SCLXWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLX
$0.04−0.00 (-1.53%)
Close on Oct 30, 2026Market cap $17.50MP/E –Yield –
Scilex free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Scilex's free cash flow for the twelve months ending Dec 31, 2024 was $19.35M. For fiscal 2025 it was $3.68M, down 81.0% from the year before. The highest annual figure on record is $19.35M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.68M | -81.0% |
| FY2024 | Dec 31, 2024 | $19.35M | – |
| FY2023 | Dec 31, 2023 | -$20.74M | – |
| FY2022 | Dec 31, 2022 | -$21.27M | – |
| FY2021 | Dec 31, 2021 | -$28.66M | – |
| FY2020 | Dec 31, 2020 | -$31.49M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $2.53M | – |
| Q3 FY2024 | Sep 30, 2024 | $5.11M | +102.4% |
| Q4 FY2023 | Dec 31, 2023 | -$5.39M | – |
| Q3 FY2023 | Sep 30, 2023 | $5.88M | – |
| Q4 FY2022 | Dec 31, 2022 | -$725.00K | – |
| Q3 FY2022 | Sep 30, 2022 | $2.53M | – |